"New Drug Shows Promise against Psoriasis" –Robert Preidt
Many patients with psoriasis showed significant improvement when taking an experimental drug called ixekizumab, according to a late-stage, phase 3 clinical trial. “This represents another in a series of recent breakthroughs in the treatment of psoriasis," said Andrew Alexis, MD, Chair of the Department of Dermatology at Mount Sinai St. Luke's and Mount Sinai Roosevelt. "In addition to improving or clearing the visible features of psoriasis, treatment with ixekizumab also resulted in significant improvement in quality of life.”
- Andrew Alexis, MD, MPH, Associate Professor, Dermatology, Icahn School of Medicine at Mount Sinai, Director, The Skin of Color Center at Mount Sinai, Site Chair, Department of Dermatology, Mount Sinai St. Luke’s and Mount Sinai West